Analysis of the effectiveness of schemes antiemetics in control of nausea and vomiting induced by chemotherapy and therapies target

• Grant number: 13/04687-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): June 01, 2013
• Effective date (End): May 31, 2014
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Fernanda Maris Peria
• Grantee: Lauro Monelli Stocco
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Cancer is a disease whose incidence has been increasing worldwide over the years, as well as the prevalence and mortality caused by this disease. Chemotherapy is the primary systemic treatment available for the majority of tumors and, due to lack specificity for malignant cells, these drugs have many side effects. Nausea and vomiting induced by anticancer treatment (NIVQ) stand out among the symptoms more difficult to control in cancer patients with impact on quality of life and adherence to treatment. There are gaps in the literature regarding the effectiveness of the scheme prescribed prophylactic antiemetic medications and the risk of emesis from chemotherapy, and this prophylaxis in various situations can underestimate or overestimate these adverse effects. Objective: the objective of this work is to identify and grade the NIVQ in cancer patients and to correlate the risk of emesis from chemotherapy and targeted therapies with prophylactic antiemetic regimen of prescribed evaluating the effectiveness of this prophylaxis. Patients and methods: we will analyze 200 patients with histological diagnosis of malignancy treated with chemotherapy and / or targeted therapies performed in Central Chemotherapy HC-FMRP-USP. Will be included only patients from the 2nd cycle of treatment. Patients will be interviewed following a specific script (Annex A) while they are receiving the infusion of medications and will also be collected from medical records and socio-demographic information about the disease and treatment. The study will be submitted for consideration by the Ethics in Research of the Hospital of the Faculty of Medicine of Ribeirão Preto - USP and all patients will be enrolled only after an explanation of the work, clarification of doubts, agreement and signing the Consent Clarified by the patient (Annex B). (AU)